Skip to main content
European Commission logo print header

Quality of life following adherence therapy for people disabled by schizophrenia and their carers (QUATRO)


Ant psychotic medication has well-established effectiveness in the treatment of people with schizophrenia. However, adherence to medication is a very common problem, and non-adherence increases the risk of relapse disability, and poor quality of life. The "Quality of Life following Adherence Therapy for People Disabled by Schizophrenia and their Carers" study is a randomised controlled trial and will investigate the effectiveness and cost effectiveness of adherence therapy designed to improve quality of life among schizophrenic patients and their carers. The study is expected to contribute to evidence-based practice in the care for people who suffer from schizophrenia, and their carers, across Europe.

Call for proposal

Data not available


De crespigny park, denmark hill
SE5 8AF London
United Kingdom

See on map

EU contribution
No data

Participants (3)